［1］Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy\[J\]. Nat Rev Cancer, 2012, 12(4):252-264.［2］Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (antiPD1) in melanoma \[J\]. N Engl J Med, 2013, 369(2):134-144.［3］Brahmer JR，Tykodi SS，Chow LQ，et al.Safety and activity of antiPDL1 antibody in patients with advanced cancer \[J\]. N Engl J Med, 2012, 366(26) : 2455-2465．［4］Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of antiPD1 antibody in cancer \[J\]. N Engl J Med, 2012, 366(26):2443-2454.［5］Kleffel S, Posch C, Barthel SR, et al. Melanoma cellintrinsic PD1 receptor functions promote tumor growth \[J\]. Cell,2015,162(6):1242-1256.［6］Yuan J, Zhang J, Zhu Y, et al. Programmed deathligand1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance \[J\].Oncotarget, 2016，7（26）：39671-39679.［7］Bger C, Behrens HM, Mathiak M, et al. PDL1 is an independent prognostic predictor in gastric cancer of Western patients\[J\]. Oncotarget, 2016,7(17):24269-24283.［8］Derks S, Liao X, Chiaravalli AM, et al. Abundant PDL1 expression in EpsteinBarr virusinfected gastric cancers \[J\]. Oncotarget, 2016,7(22):32925-32932.［9］Tumeh PC, Harview CL, Yearley JH, et al. PD1 blockade induces responses by inhibiting adaptive immune resisitance \[J\].Nature, 2014,515(7528):568-571.［10］Schatton T, Schutte U, Frank NY,et al. Modulation of Tcell activation by malignant melanoma initiating cells \[J\].Cancer Res,2010,70(2):697-708.［11］Chen L, Deng H, Lu M, et al. B7H1 expression associates with tumor invasion and predicts patient′s survival in human esophageal cancer \[J\].Int J Clin Exp Pathol,2014, 7(9):6015-6023.［12］Kataoka K, Shiraishi Y, Takeda Y,et al. Aberrant PDL1 expression through 3′UTR disruption in multiple cancers\[J\].Nature,2016, 534(7607):402-406.
2016, Vol. 26 
